Compared to mycophenolate mofetil (MMF) regimen what was the result of everolimus regimen on combined rate of death, graft loss and LTFU at month 12?
The eGFR levels were higher for the everolimus group through the study but the treatment comparisons did not show any statistically significant differences between the groups at any time point (Table 4; see also Additional file 2).